close Icon

Development of a novel antibody for treatment and prevention of respiratory disease

Respiratory infections such as SARS coronaviruses trigger a mucosal immune response. We are developing a novel class of antibody to provide enhanced protection against SARS-CoV-2 and improved therapeutic performance in the treatment of COVID-19 and other respiratory infections compared to IgG antibodies. 

We aim to develop the world’s first mucosally-targeted therapeutic and pre-exposure prophylactic antibody aimed at treating COVID-19, and blocking transmission and preventing new infections, respectively.


Our strategy is to develop two products: (1) an intramuscular or intravenous delivered purified antibody for the treatment of COVID-19 or use as a long-lasting prophylactic to supplement existing immunity; and (2) an inhalable version of the antibody for the prevention of SARS-CoV-2 infection. 

Our antibody system is a platform technology that could be adapted for other pathogens for which no vaccines or treatments are currently available. These include norovirus, RSV, and other enteric and mucosal pathogens. 

SQUARE Jen.Barnes 002 WEB

Jennifer Barnes

Contact Jennifer Barnes for more information about this project.



  • DJPR